Uniphar PLC
ISEQ:UPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (8.6), the stock would be worth €4.09 (2% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.7 | €4.16 |
0%
|
| 3-Year Average | 8.6 | €4.09 |
-2%
|
| 5-Year Average | 13.8 | €6.59 |
+58%
|
| Industry Average | 33 | €15.79 |
+280%
|
| Country Average | 12.6 | €6.02 |
+45%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| IE |
U
|
Uniphar PLC
ISEQ:UPR
|
1.1B EUR | 8.7 | 21.1 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
100.1B USD | 12.5 | 23.1 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.1B USD | 19.7 | 36.4 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.5B USD | 19.8 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
46.1B USD | 6.8 | 27.7 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.3B AUD | 40.9 | 35.5 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.4B CNY | 21.6 | 11.1 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 8.9 | 21.5 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
58.5B CNY | 136.2 | 20.6 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -236.8 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.6B HKD | -35.6 | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 5.5 |
| Median | 12.6 |
| 70th Percentile | 22.8 |
| Max | 6 997.4 |
Other Multiples
Uniphar PLC
Glance View
Uniphar Plc engages in the provision of pre-wholesale and wholesale pharmaceutical distribution. The company is headquartered in Dublin, Dublin and currently employs 2,920 full-time employees. The company went IPO on 2019-07-17. The firm is a diversified healthcare services company. The company serves multinational pharmaceutical and medical technology manufacturers across three divisions: Commercial & Clinical, Product Access and Supply Chain & Retail. Through commercial & clinical division, the Company provides sales, marketing and distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Product Access division offers two service offerings: On Demand Access and Exclusive Access. On Demand Access is a pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists. Exclusive Access is a manufacturer led solution for controlling the release of specialty medicines for specifically approved patient populations. Supply Chain & Retail provides both pre-wholesale distribution and wholesale distribution of pharmaceutical, healthcare and animal health products.
